翻訳と辞書 |
Matrixx Initiatives, Inc. v. Siracusano : ウィキペディア英語版 | Matrixx Initiatives, Inc. v. Siracusano
''Matrixx Initiatives, Inc. v. Siracusano'' was a case decided by the Supreme Court of the United States on March 22, 2011. The case considered whether a plaintiff can state a claim for securities fraud under §10(b) of the Securities Exchange Act of 1934, as amended, 15 U.S.C. (§78j(b) ), and Securities and Exchange Commission Rule 10b-5, 17 CFR §240.10b-5 (2010), based on a pharmaceutical company's failure to disclose reports of adverse events associated with a product if the reports do not find statistically significant evidence that the adverse effects may be caused by the use of the product. In a 9–0 decision delivered by Justice Sonia Sotomayor, the Court affirmed the Court of Appeals for the Ninth Circuit's ruling that the respondents, plaintiffs in a securities fraud class action against Matrixx Initiatives, Inc., and three Matrixx executives, have stated a claim under §10(b) and Rule 10b-5. == Parties ==
* Petitioners: Matrixx Initiatives, Inc., Carl Johnson, William Hemelt, and Timothy Clarot (collectively "Matrixx") * Respondents: James Siracusano and NECA-IBEW Pension Fund, on behalf of themselves and all others similarly situated who purchased Matrixx securities between October 22, 2003, and February 6, 2004
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Matrixx Initiatives, Inc. v. Siracusano」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|